Pfizer Makes Significant Entry into CAR-T Field with Cellectis Pact
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 8 (Table of Contents)
Published: 22 Aug-2014
DOI: 10.3833/pdr.v2014.i8.2052 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Following, somewhat belatedly, in the footsteps of Novartis and Celgene, Pfizer has entered the chimeric antigen receptor T-cell (CAR-T) immunotherapy field by forming a broad multitarget alliance with French biotech Cellectis that has a potential value in excess of US$2...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS